These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Nov. 7 through Nov. 13, 2024. Source: VerityData

Increases in Holdings

Bitdeer Technologies Tether Holdings increased its stake in the blockchain specialist to 30,006,395 shares. The cryptocurrency company bought 4,291,702 Bitdeer Technologies shares from Sept. 9 through Nov. 5 at prices ranging from $5.70 to $7.95 each.

Following the latest purchases, Tether Holdings owns 28.8% of Bitdeer's outstanding stock.

PBF Energy Carlos Slim increased his holdings in the petroleum refiner to 26,197,498 shares. The Mexican billionaire purchased 1,246,000 PBF Energy shares from Oct. 28 through Nov. 5 at prices ranging from $28.10 to $31.60 each.

Following the purchases, Slim owns 22.8% of PBF's outstanding stock.

Decreases in Holdings

Bristow Group South Dakota Investment Council lowered its stake in the provider of vertical flight solutions to 3,693,665 shares. South Dakota Investment Council sold 75,000 Bristow Group shares on Nov. 6 at prices ranging from $36.29 to $38.15 each.

Following the latest sales, South Dakota Investment Council continues to own 12.9% of Bristow Group's outstanding stock.

Impinj Sylebra Capital decreased its stake in the wireless-chip maker to 2,222,352 shares. Sylebra Capital did so through the sale of 975,000 Impinj shares from Oct. 29 through Nov. 8 at prices ranging from $195 to $203.09 each.

Following the latest sales, Sylebra Capital continues to own 7.9% of Impinj's outstanding stock. Shares have more than doubled in value during the year to date.

Janux Therapeutics Avalon Ventures XI reduced its stake in the clinical-stage biopharmaceutical company to 2,146,482 shares. Avalon Ventures sold 550,620 Janux Therapeutics shares from Oct. 25 through Nov. 1 at prices ranging from $52.70 to $55.46 each.

Following the latest sales, Avalon Ventures owns 4.1% of Janux Therapeutics' outstanding stock, below the 5% threshold that would require Avalon to report further sales of Janux Therapeutics stock. Shares of Janux have rocketed more than 370% in 2024.

GeneDX Holdings Opko Health reduced its stake in the health-intelligence company to 1,746,674 shares. Opko Health did so through the sale of 310,000 GeneDx Holdings' shares from Nov. 4 through Nov. 8 at prices ranging from $74.90 to $80 each. This follows Opko Health's prior sales of 951,729 GeneDx Holdings shares from July 29 through Sept. 17 at prices ranging from $29.35 to $38.29 each, and the sale of 435,200 shares in July at prices ranging from $26.46 to $34.66 each.

Following the sales, Opko Health continues to own 6.4% of GeneDx Holdings's outstanding stock. Shares of GeneDx Holdings have surged to a recent price of more than $78 from $2.75 at the end of 2023. In late October, CEO Katherine Stueland noted that the company achieved profitability in the third quarter.

Email: editors@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

November 15, 2024 20:34 ET (01:34 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.